UTMD Q4 EPS $1.253, up 11% YoY; FY22 EPS $4.522, up 12%; dividend raised to $0.295

UTAH MEDICAL PRODUCTS INC

2022-FY EPS reported $4.52 revenue$52,281,000

Q4 revenue $13.6M (+5.1% YoY); FY22 revenue $52.3M (+6.6% YoY); constant currency sales up ~10% for the year.
Gross margin declined to 61.3% (Q4) and 61.6% (FY22) from 62.8%/63.0% on higher manufacturing costs and raw materials.
FY22 operating income $19.8M (+4.8%) despite $670K in litigation expenses vs $22K in 2021; cash & investments rose to $75.1M.
Repurchased 30,105 shares at $82.88 in Q2 2022; quarterly dividend increased to $0.295/share effective Jan 2023 payment.
Outstanding shares 3.63M at year-end; diluted shares 3.64M; no debt on balance sheet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.